Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Siegfried Wassenberg

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Annals of the Rheumatic Diseases|June 29, 2012
Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated studyJacqueline Detert, Hans Bastian, Joachim Listing, et al.
Journal of Clinical Medicine|December 23, 2022
Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA)Michaela Koehm, Ann C Foldenauer, Tanja Rossmanith, et al.
The Journal of Rheumatology|May 8, 2003
Repair of erosions in rheumatoid arthritis does occur. Results from 2 studies by the OMERACT Subcommittee on Healing of ErosionsJohn T Sharp, Désirée Van Der Heijde, Maarten Boers, et al.
Arthritis and Rheumatism|April 9, 2005
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)Christian E Antoni, Arthur Kavanaugh, Bruce Kirkham, et al.
The Journal of Rheumatology|April 3, 2008
Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)Christian E Antoni, Arthur Kavanaugh, Désirée van der Heijde, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 1, 2022
The Efficacy of Short-Term Bridging Strategies With High- and Low-Dose Prednisolone on Radiographic and Clinical Outcomes in Active Early Rheumatoid Arthritis: A Double-Blind, Randomized, Placebo-Controlled TrialDietmar Krause, Anna Mai, Renate Klaassen-Mielke, et al.
Rheumatology International|August 15, 2013
German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugsKatinka Albrecht, Klaus Krüger, Jürgen Wollenhaupt, et al.
Arthritis Research & Therapy|May 17, 2011
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)Hans-Peter Tony, Gerd Burmester, Hendrik Schulze-Koops, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Annals of the Rheumatic Diseases|June 29, 2012
Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated studyJacqueline Detert, Hans Bastian, Joachim Listing, et al.
Journal of Clinical Medicine|December 23, 2022
Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA)Michaela Koehm, Ann C Foldenauer, Tanja Rossmanith, et al.
The Journal of Rheumatology|May 8, 2003
Repair of erosions in rheumatoid arthritis does occur. Results from 2 studies by the OMERACT Subcommittee on Healing of ErosionsJohn T Sharp, Désirée Van Der Heijde, Maarten Boers, et al.
Arthritis and Rheumatism|April 9, 2005
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)Christian E Antoni, Arthur Kavanaugh, Bruce Kirkham, et al.
The Journal of Rheumatology|April 3, 2008
Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)Christian E Antoni, Arthur Kavanaugh, Désirée van der Heijde, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 1, 2022
The Efficacy of Short-Term Bridging Strategies With High- and Low-Dose Prednisolone on Radiographic and Clinical Outcomes in Active Early Rheumatoid Arthritis: A Double-Blind, Randomized, Placebo-Controlled TrialDietmar Krause, Anna Mai, Renate Klaassen-Mielke, et al.
Rheumatology International|August 15, 2013
German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugsKatinka Albrecht, Klaus Krüger, Jürgen Wollenhaupt, et al.
Arthritis Research & Therapy|May 17, 2011
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)Hans-Peter Tony, Gerd Burmester, Hendrik Schulze-Koops, et al.
Pageof 5